title: Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
abstract: The recent arrival of the target-specific oral anticoagulants (TSOACs) offers potential advantages in the field of anticoagulation. However, there are no rapid and accurate and routinely available laboratory assays to evaluate their contribution to clinical bleeding. With the expanding clinical indications for the TSOACs, and the arrival of newer reversal agents on the market, the emergency clinician will need to be familiar with drug specifics as well as methods for anticoagulation reversal. This review offers a summary of the literature and some practical strategies for the approach to the patient taking TSOACs and the management of bleeding in these cases.
authors: Denver Health Residency in Emergency Medicine, Denver, CO 80207. Electronic address: millermp123@gmail.com.
authors: Michael P
authors: MP
authors: Miller
authors: University of Colorado Skaggs, School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045; University of Colorado, Anschutz Medical Campus Clinical Specialist-Anticoagulation/Cardiology University of Colorado Hospital, Aurora, CO 80045; C238-V20 Pharmacy & Pharmaceutical Sciences, Aurora, CO 80045. Electronic address: toby.trujillo@ucdenver.edu.
authors: Toby C
authors: TC
authors: Trujillo
authors: Department of Emergency Medicine, University of Colorado, School of Medicine, Aurora, CO 80045. Electronic address: Kristen.nordenholz@ucdenver.edu.
authors: Kristen E
authors: KE
authors: Nordenholz
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000069604:Dabigatran; D004638:Emergency Treatment; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran